--- title: "Vericel | 8-K: FY2026 Q1 Revenue Beats Estimate at USD 68.43 M" type: "News" locale: "en" url: "https://longbridge.com/en/news/285546162.md" datetime: "2026-05-07T11:59:43.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/285546162.md) - [en](https://longbridge.com/en/news/285546162.md) - [zh-HK](https://longbridge.com/zh-HK/news/285546162.md) --- # Vericel | 8-K: FY2026 Q1 Revenue Beats Estimate at USD 68.43 M Revenue: As of FY2026 Q1, the actual value is USD 68.43 M, beating the estimate of USD 63.62 M. EPS: As of FY2026 Q1, the actual value is USD -0.12. EBIT: As of FY2026 Q1, the actual value is USD -9.755 M. #### First Quarter 2026 Financial Highlights - **Total Revenue**: Vericel Corporation reported a total net revenue of $68.4 million for the first quarter ended March 31, 2026, representing a 30% increase compared to $52.6 million in the first quarter of 2025. - **Segment Revenue**: - MACI net revenue increased by 22% to $56.4 million, up from $46.3 million in the prior-year quarter. - Burn Care net revenue grew by 91% to $12.0 million. - Epicel net revenue was $10.9 million, compared to $5.0 million in the first quarter of 2025, showing a 119% growth. - NexoBrid net revenue was $1.1 million, down from $1.3 million in the first quarter of 2025. - **Gross Margin**: The gross margin for the quarter was 72%, an increase from 69% in the first quarter of 2025, with gross profit reaching $49.3 million compared to $36.3 million in the prior year. - **Operating Costs**: - Total operating expenses increased to $57.3 million from $49.1 million in the first quarter of 2025. - Research and development expenses were $8.1 million in Q1 2026, up from $7.3 million in Q1 2025. - Selling, general and administrative expenses were $49.2 million in Q1 2026, up from $41.8 million in Q1 2025. - **Operating Profit**: The company reported a loss from operations of - $8.1 million, an improvement from a loss of - $12.8 million in the first quarter of 2025. - **Net Loss**: Vericel Corporation recorded a net loss of - $6.3 million, or - $0.12 per diluted share, a reduction from a net loss of - $11.2 million, or - $0.23 per diluted share, in the first quarter of 2025. - **Adjusted EBITDA**: Non-GAAP adjusted EBITDA increased by 195% to $9.6 million, or 14% of revenue, compared to $3.2 million, or 6% of revenue, in the first quarter of 2025. - **Cash Flow**: - Operating cash flow was $16.4 million for the quarter, significantly up from $6.6 million in the first quarter of 2025. - Free cash flow was $15.1 million, a substantial improvement from - $7.6 million in the first quarter of 2025. - Capital expenditures were - $1.3 million, compared to - $14.2 million in the prior-year quarter. - Net cash used in investing activities was - $4.2 million, compared to - $15.1 million in Q1 2025. - Net cash used in financing activities was - $3.0 million, compared to $3.2 million provided by financing activities in Q1 2025. - **Cash and Investments**: The company held approximately $211 million in cash and investments and had no debt as of March 31, 2026. #### Operational Metrics and Business Highlights - Vericel achieved record first quarter total revenue, MACI revenue, and Burn Care revenue. - MACI revenue growth has been 20% or more for the fourth consecutive quarter, with a four-quarter trailing revenue growth rate of 23%. - The company reported double-digit MACI biopsy and implant growth, with record first quarter MACI biopsies, implants, and biopsy and implanting surgeons. - Vericel announced a BARDA award valued at up to $197 million for the procurement and advanced development of NexoBrid. - FDA approval was received for MACI commercial manufacturing at the company’s new state-of-the-art facility. #### 2026 Financial Guidance (Outlook) Vericel Corporation raised its full-year 2026 total revenue guidance by $10 million to a range of $326 million to $336 million, with MACI revenue projected at $282 million to $288 million and Burn Care revenue increased to $44 million to $48 million. The company reaffirmed its full-year profitability guidance, expecting a gross margin of approximately 75% and an adjusted EBITDA margin of approximately 27%. ### Related Stocks - [VCEL.US](https://longbridge.com/en/quote/VCEL.US.md) ## Related News & Research - [Vericel Independent Director Paul Wotton Sells 35% Of Holding](https://longbridge.com/en/news/286543900.md) - [Vericel Corporation $VCEL Stock Position Reduced by Truist Financial Corp](https://longbridge.com/en/news/286758697.md) - [Assessing Vericel (VCEL) Valuation After Recent Share Price Weakness And Contrasting Growth Narratives](https://longbridge.com/en/news/285959566.md) - [Vericel forecasts $326M-$336M 2026 revenue as BARDA-backed NexoBrid procurement begins in H2](https://longbridge.com/en/news/285660366.md) - [Vericel (NASDAQ:VCEL) Stock Rating Lowered by Wall Street Zen](https://longbridge.com/en/news/272893408.md)